Africans unite against sleeping-sickness

27 February 2006

An international gathering in Angola has convened to discuss ways of improving cooperation against trypanoso-miasis (sleeping-sickness), a disease which afflicts between 100,000 and 350,000 people annually across the continent. The two day conference, held in Luanda, Angola, was attended by representatives from the African states of Angola, the Democratic Republic of Congo, the Republic of Congo, Sudan and Uganda, as well as the World Health Organization's Angola representative, Fatoumatou Diallo.

New treatments, diagnostics need

Angola's Deputy Minister of Science and Technology, Pedro Sebastiao Teta, opened the conference with a speech about the need for more research into the disease, which puts at risk over 60 million Africans. He added that the lack of organization in the education system, a shortage of qualified managers, the inadequate infrastructure and the brain drain of talent away from Africa was holding back the continent's scientific and technological progress. Specific areas of necessary improvement are "the rein-forcement of, and clinical trials, for new medicines," said Mr Teta, as well as diagnostic techniques.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight